BAX

Business Context and Reporting Period

Company: Baxter International Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2001
Headquarters: Deerfield, Illinois

Baxter is a global leader in critical therapies for life-threatening conditions, operating through three primary segments: Medication Delivery (IV solutions and specialty products), BioScience (biopharmaceuticals, blood collection, and vaccines), and Renal (kidney disease treatment products and services). The company manufactures in 28 countries and sells in over 100 countries, generating approximately 50% of its revenue outside the United States.

Key Financial Metrics

Note: Specific revenue, net income, and cash flow totals are incorporated by reference from the Annual Report and are not explicitly stated in the provided text. The following metrics are available from the filing text:

• Research & Development (R&D) Expenditures: $427 million (2001), compared to $379 million in 2000 and $332 million in 1999.
• Capital Expenditures (Continuing Operations): $669 million (2001), compared to $547 million in 2000 and $529 million in 1999.
• Leased Equipment Additions: $118 million (2001).
• Debt Ratings (as of March 1, 2002): A3 (Moody's), A (S&P), A (Fitch).
• Market Capitalization (Non-Affiliate): Approximately $33.1 billion (based on March 1, 2002 closing price of $55.37).
• Shares Outstanding: 599,868,645 (as of February 28, 2002).
• Employees: Approximately 48,000 (as of December 31, 2001).

Valuation and Qualifying Accounts (in millions)

Material Changes and Operational Highlights

• Acquisitions: Expanded oncology business via acquisition of ASTA Medica Oncology (Germany) and Cook Pharmaceutical Solutions (injectable drug formulation). Acquired assets and exclusive rights to a proprietary recombinant drug for anemia treatment.
• Product Launches & Approvals: Received European licensure for Ceprotin (protein C concentrate) and additional approvals for NeisVac-C (meningitis C vaccine). Filed for FDA approval of ALYX automated blood collection system and INTERCEPT Blood System in Europe.
• Strategic Shifts: Increased focus on higher-margin specialty products outside the U.S. and expansion of "integrated care" strategies in renal services.
• Legal Reserves: Litigation reserves decreased from $326 million in 2000 to $220 million in 2001, reflecting settlements and payments.

Outlook, Risks, and Contingencies

Management Commentary and Outlook

Management expects to accelerate growth through the expansion of higher-margin specialty products in international markets. The company plans to introduce new products in 2002, including the Syntra synthetic HD dialyzer, Extraneal PD solution, and HomeChoice Pediatric automated PD machine. The company anticipates continued pricing and market share pressures due to industry consolidation.

Material Risks and Legal Proceedings

• Mammary Implant Litigation: Defendant in 303 lawsuits (approx. 618 plaintiffs) regarding silicone implants. A class action settlement (Revised Settlement) is in place. Insurers have committed over $800 million to cover losses.
• Plasma-Based Therapies Litigation: Defendant in claims regarding HIV infection from factor concentrates (1978-1985). A U.S. class action settlement is active, and a settlement for Japanese cases has been agreed upon. Insurance coverage is expected for a substantial portion of costs.
• Dialyzer Safety Issues: Facing lawsuits and government investigations in Spain and Croatia regarding patient deaths linked to Althane series dialyzers. Preliminary tests suggested a processing fluid issue at the Ronneby, Sweden facility. Settlements have been reached with some families.
• Pricing Investigations: Subject to civil lawsuits and government investigations regarding alleged artificially inflated pricing of Medicare and Medicaid eligible drugs.
• Environmental: Named as a potentially responsible party for six hazardous waste sites with an estimated exposure of $2 million (accrued).

Investor Verification Checklist

• Verify the full consolidated revenue, net income, and cash flow figures in the Annual Report to Stockholders (incorporated by reference), as they are not explicitly detailed in this 10-K text.
• Review the status of the mammary implant and plasma-based therapy litigation settlements to confirm the adequacy of the $220 million litigation reserve.
• Monitor the outcome of the Althane dialyzer investigations in Spain and Croatia and any potential expansion of liability to other markets.
• Assess the impact of the strengthening U.S. dollar on international revenue growth, as noted in the risk factors.
• Confirm the progress of new product approvals (ALYX, INTERCEPT, Extraneal) scheduled for 2002.